Journal
VACCINE
Volume 28, Issue 32, Pages 5179-5184Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.05.075
Keywords
Tuberculosis; NALT; Ad85A
Categories
Funding
- UK Medical Research Council [60701235]
- Medical Research Council [G0701235] Funding Source: researchfish
- MRC [G0701235] Funding Source: UKRI
Ask authors/readers for more resources
Intra-nasal administration of a recombinant adenovirus expressing Mycobacterium tuberculosis antigen 85A (Ad85A) has been shown to provide protection against challenge with M. tuberculosis. However the role of the upper respiratory tract associated lymphoid tissue, specifically the nasal associated lymphoid tissue (NALT), in providing protection has yet to be elucidated. Here we administered Ad85A to BALB/c mice alone or following BCG priming, using intranasal inocula targeting the whole respiratory tract or only the NALT, to show that Ad85A induces an immune response in the NALT insufficient to provide protection. Rather, Ad85A delivered through the respiratory tract must induce a deep lung immune response in order to protect against M. tuberculosis. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available